- Trial phase
- Approved
- Time to market
- Already approved and commercially available since January 2022.
- Why 4/10
- Cortrophin Gel is already FDA-approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next 12 months. The defining binary catalyst has passed. The next hard catalyst is the Q4 2026 earnings report (expected early February 2027) for commercial revenue metrics, but quarterly sales results are not a binary regulatory catalyst. Per the rubric, an approved drug with no pending regulatory decision scores 3-5; Cortrophin is ANIP's largest product (~45% of revenue) but the company also has generics, ILUVIEN, and the Egetis acquisition diversifying the thesis, so a score of 4 is appropriate.
Cortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.
Price Chart
Executive Summary
Cortrophin Gel (Purified Cortrophin Gel, repository corticotropin injection) is an FDA-approved adrenocorticotropic hormone (ACTH) therapy for multiple chronic autoimmune disorders, marketed by ANI Pharmaceuticals (Nasdaq: ANIP). It is the only FDA-approved purified corticotropin product and competes with Mallinckrodt's Acthar Gel in a market driven by chronic autoimmune indications including multiple sclerosis exacerbations, rheumatoid arthritis, and acute gouty arthritis flares. Cortrophin Gel is ANIP's largest product, generating $138.7M in Q3 2026 (+36% YoY) and guided at $480M-$500M for full-year 2026, representing roughly 45% of total company revenue. The drug is already approved and commercially launched, so there is no pending FDA binary catalyst; the investor focus is on commercial execution, gout expansion, and specialty pharmacy capacity.
How It Works
Cortrophin Gel is a purified form of adrenocorticotropic hormone (ACTH), a naturally occurring hormone that stimulates the adrenal glands to release cortisol and other steroid hormones. This broad anti-inflammatory and immunosuppressive effect makes it useful for treating a range of autoimmune and inflammatory conditions. Unlike synthetic steroids, ACTH also acts on melanocortin receptors throughout the body, which may provide additional anti-inflammatory benefits through non-steroid pathways.
Trial Status
Cortrophin Gel was originally FDA-approved decades ago (original NDA 008975 approved 1954). ANI Pharmaceuticals launched the product commercially in January 2022. The FDA granted supplemental approvals for a 1-mL vial size for acute gout (October 2023), a prefilled syringe format (March 2025), and a labeling update (October 2026). No pivotal clinical trials are ongoing for new indications; the company is pursuing commercial expansion into gout via sales force deployment rather than new clinical data.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report (expected early February 2027): Cortrophin Gel revenue and gout expansion metrics will be key.
- Egetis Therapeutics tender offer acceptance period (Nov 20 - Dec 18, 2026): if 90% acceptance threshold is met, the acquisition closes around Dec 29, 2026, adding EMCITATE to the rare disease portfolio.
- Gout sales force expansion: continued monitoring of new prescriber adoption and patient starts in the acute gout indication.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ANI PHARMACEUTICALS INC 8-K ANIP ·Originating report